1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Chugai Pharmaceutical Co., Ltd
  6. News
  7. Summary
    4519   JP3519400000

CHUGAI PHARMACEUTICAL CO., LTD

(4519)
  Report
Delayed Japan Exchange  -  02:00 2022-06-24 am EDT
3570.00 JPY   +2.79%
06/23CHUGAI PHARMACEUTICAL : Presentation
PU
06/23Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo Nodularis
AQ
06/20Roche Unit's Hemlibra Receives Japanese Nod for Additional Indication of Acquired Hemophilia A
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Chugai Pharmaceutical : Notice of Completion of Disposal of Treasury Shares as Restricted Stock Compensation Plan

04/27/2022 | 10:44pm EDT

April 28, 2022

Name of listed company:

Chugai Pharmaceutical Co., Ltd.

Code number:

4519 (Prime Market of Tokyo Stock Exchange)

Head office:

1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo

President & CEO:

Osamu Okuda

Inquiries to:

Toshiya Sasai

Head of Corporate Communications Dept.

Tel: +81-(0)3-3273-0554

Notice of Completion of Disposal of Treasury Shares as Restricted

Stock Compensation Plan

TOKYO, April 28, 2022-- Chugai Pharmaceutical Co., Ltd. announced that disposal of treasury shares was completed today, as we announced in the press release "Notice of Disposal of Treasury Shares as Restricted Stock Compensation Plan" on March 29, 2022. The result of treasury shares is as follows.

1.

Overview of Disposal

(1) Disposal date

April 28, 2022

(2) Class and number of disposed shares

91,300 shares of Common stock of the Company

(3) Disposal price

¥4,158 per share

(4) Total value of disposed shares

¥379,625,400

(5) Allottees and number thereof;

Directors 3

46,600 shares

number of disposed shares

Vice presidents 12

17,800 shares

Employees 110

26,900 shares

###

Disclaimer

Chugai Pharmaceutical Co. Ltd. published this content on 28 April 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 April 2022 02:43:07 UTC.


© Publicnow 2022
All news about CHUGAI PHARMACEUTICAL CO., LTD
06/23CHUGAI PHARMACEUTICAL : Presentation
PU
06/23Galderma Announces Topline Results of OLYMPIA 2 Study Evaluating Nemolizumab in Prurigo..
AQ
06/20Roche Unit's Hemlibra Receives Japanese Nod for Additional Indication of Acquired Hemop..
MT
06/20Roche's Chugai, Zenyaku Kogyo Win Japanese Nod For Rituxan Drug Against Neuromyelitis O..
MT
06/20Roche's Chugai Pharmaceutical Wins Japanese Regulatory Nod For Changes To Leukemia, Ova..
MT
06/20CHUGAI PHARMACEUTICAL : Obtains Regulatory Approval for Hemlibra for Additional Indication..
PU
06/20CHUGAI PHARMACEUTICAL : Obtains Partial Change Approval for Neutrogin and Avastin Based on..
PU
06/20CHUGAI PHARMACEUTICAL : Anti-CD20 Monoclonal Antibody Rituxan Approved for the Prevention ..
PU
06/10Japan Index Trades Steadily in Red; Round One Shares Gain 9% as May Sales Exceed Pre-Pa..
MT
06/10Chugai Appeals Tokyo Court's Dismissal of Patent Infringement Lawsuit Against Sawai, Ni..
MT
More news
Analyst Recommendations on CHUGAI PHARMACEUTICAL CO., LTD
More recommendations
Financials
Sales 2022 1 185 B 8 774 M 8 774 M
Net income 2022 342 B 2 529 M 2 529 M
Net cash 2022 571 B 4 225 M 4 225 M
P/E ratio 2022 17,2x
Yield 2022 2,18%
Capitalization 5 871 B 43 454 M 43 454 M
EV / Sales 2022 4,47x
EV / Sales 2023 4,95x
Nbr of Employees 7 664
Free-Float 37,8%
Chart CHUGAI PHARMACEUTICAL CO., LTD
Duration : Period :
Chugai Pharmaceutical Co., Ltd Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CHUGAI PHARMACEUTICAL CO., LTD
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 13
Last Close Price 3 570,00 JPY
Average target price 4 639,23 JPY
Spread / Average Target 30,0%
EPS Revisions
Managers and Directors
Tatsuro Kosaka Manager-Pharmaceutical Business Strategy Office
Osamu Okuda Manager-Life Cycle Management II
Itagaki Toshiaki CFO, Manager-Information Technology & Accounting
Hisafumi Okabe Senior Executive Officer & Head-Research
Junichi Nezu Executive Officer, GM-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
CHUGAI PHARMACEUTICAL CO., LTD-4.42%43 454
JOHNSON & JOHNSON5.02%479 678
ELI LILLY AND COMPANY13.21%293 110
PFIZER, INC.-15.17%289 466
ROCHE HOLDING AG-15.91%272 090
ABBVIE INC.12.51%269 202